2026-04-17T06:21:13Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1803722025-11-20T15:04:03Zcom_2072_1057col_2072_478916col_2072_478917
Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)
Genescà, Eulàlia
Morgades, Mireia
González Gil, Celia
Fuster Tormo, Francisco
Haferlach, Claudia
Meggendorfer, Manja
Montesinos, Pau
Barba, Pere
Gil, Cristina
Coll, Rosa
Moreno, María José
Martínez Carballeira, Daniel
García Cadenas, Irene
Vives, Susana
Ribera, Jordi
González Campos, José
Díaz Beyà, Marina
Mercadal, Santiago
Artola, María Teresa
Cladera, Antonia
Tormo, Mar
Bermúdez, Arancha
Vall Llovera, Ferran
Martínez Sánchez, Pilar
Amigo, María Luz
Monsalvo, Silvia
Novo, Andrés
Cervera, Marta
García Guiñon, Antonio
Ciudad, Juana
Cervera, José
Hernández Rivas, Jesús María
Granada, Isabel
Haferlach, Torsten
Orfao, Alberto
Solé, Francesc
Ribera, Josep Maria
Citogenètica humana
Leucèmia
Pronòstic mèdic
Human cytogenetics
Leukemia
Prognosis
The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of ≥3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with ≥3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corresponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying karyotypes with ≥3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), independently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Additional molecular analyses of patients carrying ≥3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel targeted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients.
2021-10-04T07:32:18Z
2021-10-04T07:32:18Z
2021-10-01
2021-10-01T11:41:04Z
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Reproducció del document publicat a: https://doi.org/10.1016/j.leukres.2021.106612
Leukemia Research, 2021, vol. 109, p. 106612
https://doi.org/10.1016/j.leukres.2021.106612
cc by-nc-nd (c) Genescà, Eulàlia et al, 2021
http://creativecommons.org/licenses/by-nc-nd/3.0/es/
info:eu-repo/semantics/openAccess
Elsevier BV
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))